



REVIEW ARTICLE



Emerging biological functions of ribonuclease 1 and angiogenin

Emily R. Garnett and Ronald T. Raines

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA

ABSTRACT

Pancreatic-type ribonucleases (ptRNases) are a large family of vertebrate-specific secretory endoribonucleases. These enzymes catalyze the degradation of many RNA substrates and thereby mediate a variety of biological functions. Though the homology of ptRNases has informed biochemical characterization and evolutionary analyses, the understanding of their biological roles is incomplete. Here, we review the functions of two ptRNases: RNase 1 and angiogenin. RNase 1, which is an abundant ptRNase with high catalytic activity, has newly discovered roles in inflammation and blood coagulation. Angiogenin, which promotes neovascularization, is now known to play roles in the progression of cancer and amyotrophic lateral sclerosis, as well as in the cellular stress response. Ongoing work is illuminating the biology of these and other ptRNases.

Abbreviations: CDK: cyclin-dependent kinase; EGFR: epidermal growth factor receptor; EphA4: ephrin A4; ERK: extracellular signal-regulating kinase; eRNA: extracellular RNA; HIF-1 α : hypoxia-inducible factor 1- α ; HPSC: hematopoietic stem/progenitor cell; lncRNA: long non-coding RNA; miRNA: microRNA; iNOS: inducible nitric oxide synthase; NoRC: nucleolar remodeling complex; piwiRNA: piwi-interacting RNA; PKC: protein kinase C; poly(A): poly(adenylic acid); poly(C): poly(cytidylic acid); poly(G): poly(guanylic acid); poly(I): poly(inosinic acid); poly(U): poly(uridylic acid); pRNA: promoter-associated RNA; ptRNase: pancreatic-type ribonuclease; rDNA: ribosomal DNA; RI: ribonuclease inhibitor protein; RNase: ribonuclease; SLFN2: Schlafen 2; sncRNA: small non-coding RNA; TIP5: termination factor I-interacting protein 5; TLR7: Toll-like receptor 7

ARTICLE HISTORY

Received 25 July 2021
Revised 29 October 2021
Accepted 7 November 2021

KEYWORDS

Blood coagulation; endoribonuclease; extracellular RNA; inflammation; pancreatic-type ribonuclease; stress

Introduction

Ribonucleases (RNases) are omnipresent enzymes that operate at the crossroads of transcription and translation (Figure 1) (D'Alessio and Riordan 1997; Nicholson 2011). By catalyzing the cleavage of RNA, RNases oversee a myriad of biological niches. For example, RNA primers that promote the replication of DNA are broken down by RNase H, tRNAs for the ribosomal translation of proteins are matured by RNase P, and miRNAs that modulate the expression of other RNA transcripts are processed by Dicer and Drosha. All of these functions are highly conserved and essential for eukaryotic cells (Bernstein et al. 2003; Wang et al. 2007; Altman 2011; Reijns et al. 2012).

Vertebrates express a unique RNase superfamily, termed the vertebrate secretory or pancreatic-type ribonucleases (ptRNases) (Beintema et al. 1988; Beintema and Kleineidam 1998). In comparison to intracellular RNases, our understanding of the biological function of ptRNases is immature. The imperative for clarification has intensified because RNAs in the extracellular space

are now known to act as messengers, inflammatory mediators, and enzyme activators (Lomax et al. 2017; Lu et al. 2018).

The pancreatic-type ribonuclease superfamily

Pancreatic-type ribonucleases are perhaps the most well-studied enzyme family. The familiarity with ptRNases is due to extensive research on the prototypical member of this enzyme family, RNase A. After its detection in porcine pancreatic tissue over a century ago (Jones 1920), RNase A became the favorite model protein of the foundational years of biochemistry (Richards and Wyckoff 1971; Blackburn and Moore 1982; Raines 1998; Marshall et al. 2008). For example, RNase A was the source of the first fragment complementation system (Richards and Vithayathil 1959), the first enzyme for which an amino acid sequence was determined (Hirs et al. 1960), the first enzyme for which a mechanism of catalysis was identified (Findlay et al. 1961), the third enzyme for which a crystal structure was determined (Kantha et al. 1967), and the object of




Figure 1. Ribonucleases function at the crossroads between transcription and translation.

Nobel-prize-winning studies on amino acid sequencing (Moore and Stein 1973), protein folding (Anfinsen 1973), and solid-phase synthesis (Merrifield 1986). In addition to their seminal contributions to biochemistry as a field, these studies on RNase A laid the groundwork for understanding other ptRNases.

Characteristic biochemical features of ptRNases

ptRNases are small enzymes. RNase A is composed of 124 amino acid residues, with a molecular mass of 13.7 kDa, which is similar to that of other family members (Cho et al. 2005). Each ptRNase contains a signal peptide that directs the secretion of the protein (Zhang et al. 2002). Despite the low sequence identity between ptRNase genes (Cho et al. 2005), the three-dimensional structure of their encoded enzymes is highly conserved (Figures 2(A,B)). An invariant catalytic triad of two histidine residues and a lysine residue endows ptRNases with the ability to catalyze the cleavage of the P–O^{5'} bond on the 3' side of pyrimidine residues (Figure 3). ptRNases are cationic in character, which encourages binding to their anionic RNA substrates (Park and Raines 2001), and they have high thermostability, owing largely to the presence of intramolecular disulfide bonds (Klink et al. 2000; Ruoppolo et al. 2000; Schulenburg et al. 2010).

ptRNases are inhibited by ribonuclease inhibitor (RI), which is a 50-kDa protein that is likewise conserved in vertebrates (Lomax et al. 2014) and is expressed ubiquitously and abundantly in the cytosol of cells (Lee and Vallee 1993; Dickson et al. 2005; Sarangdhar and Allam 2021). RI comprises leucine-rich repeats (Hofsteenge et al. 1988; Kobe and Deisenhofer 1993) and is anionic, facilitating Coulombic interactions with cationic ptRNases (Johnson et al. 2007) (Figure 2(C)). The two proteins form a 1:1 complex with a K_d value near 10^{-15} M (Lee et al. 1989; Vicentini et al. 1990; Lomax et al. 2014). This extraordinary protein–protein interaction blocks access to the active site of ptRNases and squelches catalytic activity (Domachowske et al. 1998b; Spencer et al. 2014). Consequently, RI is capable of protecting cells from the action of endocytosed ptRNases,

which would otherwise degrade cellular RNAs and cause cell death (Thomas et al. 2016, 2018).

ptRNases have been identified in all vertebrate species evaluated to date. Humans express genes encoding 13 such enzymes, clustered near one another on chromosome 14 (Zhang et al. 2002). Eight of these ptRNases are classified as “canonical” (Sorrentino 2010). The remaining five exhibit more unusual features, such as the absence of one or more catalytic residues or the lack of cationic character (Cho et al. 2005). Other species also express multiple ptRNases, with gene duplication resulting in larger numbers of enzymes in some species. For example, mice express about 20 ptRNase genes, owing to duplication of the ribonucleases 2 and 3 and ribonuclease 5 (angiogenin) subfamilies (Cho et al. 2005).

Biological functions of the ptRNase superfamily

The first report on the function of RNase A claimed that the enzyme participated in ruminant digestion but was vestigial in non-ruminants (Barnard 1969). The appreciation of other biological roles have been growing for decades (Benner and Allemann 1989; D'Alessio 1993; Wang et al. 2018a; Lee et al. 2019). Antimicrobial activity has been described for a cluster of closely related ptRNases, including ribonucleases 2 and 3, as well as 6, 7, and 8 (Sorrentino 2010), which are expressed in eosinophil granules, placenta, and skin and exhibit relatively broad-spectrum cytotoxicity (Ackerman et al. 1985; Molina et al. 1988; Lehrer et al. 1989; Venge et al. 1999; Harder and Schroder 2002; Boix and Nogués 2007; Rosenberg 2008; Attery and Batra 2017) and antiviral activity (Domachowske et al. 1998a, 1998b; Ilinskaya and Mahmud 2014; Li and Boix 2021). Angiogenins have well-documented angiogenic activity, but some subfamily members have also been reported to exhibit immune activity. Ribonucleases 9 and 10, which are non-canonical members of the ptRNase superfamily, play roles in the maturation of sperm (Krutskikh et al. 2012; Westmuckett et al. 2014). For other members of the ptRNase superfamily, however, biological functions are unclear. Recent research on two particular family members, RNase 1 and




Figure 2. Structures of human RNase 1 (UniProtKB P07998), angiogenin (UniProtKB P03950), and RI (UnitProtKB P13489). (A) Ribbon diagram of RNase 1. The active-site residues (His12, Lys41, and His119; circled), four disulfide bonds, and three sites of asparagine glycosylation (Asn34, Asn76, and Asn88) are shown explicitly with CPK colors. Right, surface charges (blue, positive; red, negative). The cationic binding cleft for RNA is apparent across the middle of the structure. (B) Ribbon diagram of angiogenin. The active-site residues (His13, Lys40, and His114; circled), three disulfide bonds, and three sites of serine phosphorylation (Ser28, Ser37, and Ser87) are shown explicitly. Right, surface charges. (C) Surface charges of RI, which is highly anionic. Images were made with the program PyMOL from Schrödinger (New York, NY, USA). Atomic coordinates: RNase 1 and RI, PDB entry 1z7x (Johnson et al. 2007); angiogenin, PDB entry 1ang (Acharya et al. 1994).




Figure 3. Putative mechanism for catalysis of RNA cleavage by ptRNases, highlighting the roles of the three active-site residues (green) depicted in Figure 2 (Findlay et al. 1961; Cuchillo et al. 2011). The 2',3'-cyclic phosphodiester product can be hydrolyzed by ptRNases in a separate step (Cuchillo et al. 1993; Thompson et al. 1994).

angiogenin (RNase 5), has revealed numerous new functions for these enzymes in various biological niches, ranging from vascular homeostasis and inflammation to cellular growth and quiescence. Here, we focus on these newly identified biological roles.

Ribonuclease 1

RNase 1 is the most active catalyst of the ptRNase superfamily in humans. Its activity against single-

stranded RNA is non-specific, degrading poly(C) > poly(U) >> poly(A) as well as double-stranded RNA and RNA:DNA hybrids (Sorrentino and Libonati 1994). RNase 1 is also the most broadly expressed ptRNase, with *Rnase1* mRNA being detectable in all tissue types (Futami et al. 1997). In healthy humans, RNase 1 circulates in serum at a concentration of 250 ng/mL (Weickmann et al. 1984); this serum RNase 1 is produced predominantly by vascular endothelial cells (Landre et al. 2002; Barrabés et al. 2007). Though secreted constitutively, RNase 1 also




Figure 4. Domain swapping in the BS-RNase dimer (Kim et al. 1995a). The active-site residues (His12, Lys41, and His119) and six disulfide bonds are shown explicitly. Images were made with the program PyMOL and PDB entries 3bcm and 3bco (Merlino et al. 2008).

accumulates in Weibel–Palade bodies in endothelial cells (Fischer et al. 2011). Additionally, RNase 1 can be *N*-glycosylated at Asn34, Asn76, and Asn88 (Figure 2(A)) (Beintema 1986), a phenomenon that appears to vary with the tissue of origin (Mizuta et al. 1990; Yasuda et al. 1993; Ribó et al. 1994). A glycan at any of the three residues attenuates catalytic activity but enhances both thermostability and resistance to proteolysis (Ressler and Raines 2019). The sequon that includes Asn34 is highly conserved among vertebrate species, and a glycan there donates hydrogen bonds that “cap” the carbonyl groups of an α -helix (Kilgore et al. 2020). RNase 1 also binds to some cell-surface glycans with micromolar affinity (Eller et al. 2014), and RNase A exhibits an especially specific interaction with Globo H (Eller et al. 2015).

Early biological studies

Human RNase 1 first elicited biomedical interest when its upregulation in the plasma of patients with pancreatic cancer spurred excitement about its potential utility as a biomarker (Reddi and Holland 1976). Subsequent studies showed that RNase 1 levels were elevated not only by pancreatic cancer but also by other malignancies (Maor and Mardiney 1978; Isaacs 1981; Weickmann et al. 1984). Ultimately, the idea of using RNase 1 as a cancer biomarker was abandoned because of its upregulation in other disease states, including bacterial and viral infection (Kutas et al. 1969), smoking (Maor et al. 1978), burn injury (Coombes et al. 1978), surgery (Barlow et al. 1979), myocardial infarction (Sznajd et al. 1981), aging (Coombes et al. 1977), Alzheimer’s disease (Sajdel-Sulkowska and Marotta 1984), malnutrition (Sigulem et al. 1973), and arthritis (Oribe 1984). Nonetheless, a recent study demonstrated that RNase 1 promotes breast tumor initiation by activating signaling *via* tyrosine kinase receptor EphA4 and that high RNase 1 levels correlate with poor clinical outcomes for patients with breast cancer (Lee et al. 2021). These

findings could revive interest in the utility of RNase 1 as a biomarker for cancer.

ptRNases returned to the forefront of cancer research with the identification of ranpirnase (Onconase[®]), a ptRNase in the northern leopard frog (*Rana pipiens*) that exhibited toxicity against cancer cell lines (Darzynkiewicz et al. 1988). This cytotoxicity was attributed to its ability to enter the cytosol and degrade cellular RNA while being insensitive to inhibition by human RI (Wu et al. 1993; Lee and Raines 2008). These key attributes of ranpirnase were presaged in a ruminant ptRNase: bovine seminal ribonuclease (BS-RNase) (Dostál and Matoušek 1973; Matoušek 1973; D’Alessio et al. 1991). BS-RNase is, in its essence, a natural dimer of RNase 1. The dimer interface is unusual. Two cysteine residues evolved in this ruminant enzyme: Cys31 and Cys32. Their sulfhydryl groups form disulfide bonds with those of another monomer. The enforced proximity facilitates the swapping of N-terminal helices within the covalent dimer (Figure 4). Because dimeric BS-RNase evades RI but monomeric BS-RNase does not (Murthy and Sirdeshmukh 1992), this domain swap is critical to biological function (Cafaro et al. 1995; Kim et al. 1995a, 1995b; Gotte et al. 2012). That is because the Cys31–Cys32’ and Cys32–Cys31’ disulfide bonds are solvent-exposed and vulnerable to reduction by endogenous β -glutathione in the cytosol. Even after the reduction of these two disulfide bonds, the dimer can remain intact and thus RI-evasive because of the non-covalent interactions that ensue from the domain swap. Monomers of BS-RNase that are engineered to evade RI are highly cytotoxic, as are dimers of those monomers (Lee and Raines 2005).

The attributes of BS-RNase and ranpirnase inspired the creation of RNase 1 variants that evade association with RI (Rutkoski and Raines 2008; Lomax et al. 2012). These variants have shown promise as anti-cancer agents and led to the introduction of a clinical drug candidate (Strong et al. 2012a, 2012b). Variants of




Figure 5. Schematic of RNase 1 and angiogenin activities and substrates. RNase 1 acts primarily on targets outside of cells, where it degrades eRNAs. These eRNAs would otherwise act as activators of coagulation and inflammatory pathways. Angiogenin, in contrast, mediates its effects largely within cells, driving both cellular quiescence in response to stress *via* tRNA degradation and proliferation *via* pRNA degradation.

RNase 1 that enter the nucleolus, which is devoid of RI, provide an alternative strategy (Castro et al. 2013; Castro et al. 2021). Circular zymogens of RNase 1 that are activated by a pathogenic protease could extend the utility of cytotoxic ribonucleolytic activity beyond cancer (Windsor et al. 2019, 2021).

Extracellular RNA

The utility of RNase 1 variants as cytotoxins is established and continues to grow. Nonetheless, insight on the biological functions of RNase 1 has remained sparse. The discovery that RNA exists in the extracellular space—where RNase 1 is free to act without inhibition by RI—has led to the emergence of new ideas (Figure 5).

RNA was once thought to be unstable outside of the cellular environment (Benner 1988). After all, ptRNases

reside in the extracellular space and could degrade extracellular RNA (eRNA) species (Kamm and Smith 1972). Long ago, however, RNA was demonstrated to be released actively by frog and human cells (Stroun et al. 1978). More recent studies have shown that RNA can persist in serum long enough to permit analysis and elicit biological functions. For example, EBER1 RNAs from Epstein–Barr virus, as well as tyrosinase mRNA from melanoma cells, were isolated from serum and plasma (Lo et al. 1999; Hasselmann et al. 2001). Moreover, cancer cells release RNA at a significantly higher rate than do non-cancerous cells (Wieczorek et al. 1985; Fischer et al. 2013).

The characterization of eRNAs has revealed that almost every known class of RNA exists outside the cell. The bulk is miRNAs, mRNA, and tRNA; though, other types of RNA, such as rRNA, piwiRNA, lncRNA, and sncRNA, have also been detected in varying proportions

(Huang et al. 2013; Yuan et al. 2016; Savelyeva et al. 2017). These eRNAs are transported in a variety of contexts, including within membranous compartments, such as microvesicles, exosomes, and apoptotic bodies (Yáñez-Mó et al. 2015), as ribonucleoprotein complexes (Turchinovich et al. 2011), and bound to high-density lipoproteins (Vickers et al. 2011).

eRNA can act as a messenger between cells, driving changes in gene expression (Valadi et al. 2007; Mittelbrunn et al. 2011). eRNA does not need to encode genetic information to exert a biological function. Instead, eRNA can stimulate lymphocyte adhesion to smooth muscle by upregulating the production of adhesion molecules, such as Vcam-1, Icam-1, P-selectin, and Ccl2 in smooth muscle cells (Fischer et al. 2012). eRNA can drive macrophage polarization to an M1 (proinflammatory) phenotype, increasing the production of inflammatory markers, such as TNF α , IL-1 β , IL-6, IL-12, and iNOS (Simsekylmaz et al. 2014). eRNA also potentiates blood coagulation by acting as an anionic scaffold for the activation of the intrinsic coagulation proteases FXI, FXII, and plasma prekallikrein. These proteases are also known as “contact factors”, as their activation has long been known to be potentiated by artificial anionic substrates, such as glass and kaolin. The finding that eRNA acts as an *in vivo* activator has been appreciated, however, more recently (Nakazawa et al. 2005; Kannemeier et al. 2007). At least for its procoagulant activities, the size and secondary structure of eRNA appears to be as important as its sequence, with coagulation protease activity only potentiated with RNAs >100 nucleotides in size, and potentiated more strongly with RNAs that form a stable hairpin structure (Gansler et al. 2012). Poly(G) and poly(I) RNAs have been reported to be efficacious activators of intrinsic proteases *in vitro* (Gajsiewicz et al. 2017).

New biological roles

The discovery and characterization of eRNAs are spawning interest in ptRNases (Lomax et al. 2017; Lu et al. 2018). For example, wild-type RNase A has been shown to reduce tumor growth in mice when administered exogenously (Fischer et al. 2013). This effect could be mediated by eRNA, which drives TNF α production via activation of TNF α -converting enzyme (TACE) in macrophages to produce an inflammatory environment conducive to tumor growth (Fischer et al. 2012).

Other studies have shown similar effects of RNase 1 on inflammation in other contexts. In a mouse model of atherosclerosis, eRNA accumulated in atherosclerotic plaques and recruited macrophages to these plaques

(Simsekylmaz et al. 2014). Elevated plasma eRNA was also associated with the incidence of ischemia-reperfusion injury in patients undergoing heart surgery (Cabrera-Fuentes et al. 2015) and with edema and tissue death in a mouse model of myocardial infarction (Cabrera-Fuentes et al. 2014). These adverse effects of eRNA were blocked by the administration of exogenous RNase 1. Notably, however, RNase 1 therapy was reported to be most effective when given prophylactically, as changes engendered by eRNA exposure were irreversible by RNase 1 after the occurrence of an injury (Stieger et al. 2017). Additionally, a TLR7-overproduction mouse model of systemic lupus erythematosus suffered fewer inflammatory symptoms when RNase A was knocked in (Sun et al. 2013), resulting in extended lifespan, reduced myeloid cell number, and reduced inflammatory deposits in the kidneys and liver of mice. The pretreatment of an ischemic murine stroke model with RNase A also resulted in less edema, smaller brain lesions, and reduced vascular permeability in treated animals than controls (Fischer et al. 2007; Walberer et al. 2009). Likewise, the treatment of rats undergoing heart transplantation surgery with RNase 1 improved graft survival and reduced edema and thrombus formation (Kleinert et al. 2016).

RNase A is now known to exhibit anticoagulant activity. Treating a mouse model of arterial thrombosis resulted in the clearance of eRNA from the thrombus, delay of vascular occlusion, and reduction in thrombus size (Kannemeier et al. 2007). RNase 1-knockout mice, though viable and fertile, have high plasma eRNA levels (Garnett et al. 2019). Moreover, their plasma forms blood clots much more rapidly than does the plasma from wild-type animals. The mechanism of action of eRNA in blood clotting entails activation of intrinsic coagulation factors FXII and FXI, as well as the upstream protease plasma kallikrein (Kannemeier et al. 2007; Gajsiewicz et al. 2017). This process is linked closely to inflammation, as plasma kallikrein is a protein that, when cleaving plasma kininogen, releases bradykinin, a potent vasodilator, and vascular permeabilizing agent. Interestingly, eRNA alone spurs vascular permeabilization in a manner mediated by VEGF and nitric oxide synthase, leading to disintegration of tight junctions in cells (Fischer et al. 2007).

Given the myriad pro-inflammatory functions ascribed to eRNA and the studies conducted to date on RNase 1, the biological function of this enzyme appears to be more complex and multifaceted than appreciated previously. Early studies demonstrating the upregulation of RNase 1 in many disease states point toward a general role for RNase 1 as a regulator of inflammatory

processes, particularly in the cardiovascular system. A role for RNase 1 in this niche reflects its high compatibility with the pH of the vascular environment (Eller et al. 2014; Lomax et al. 2017), and its colocalization in endothelial cells with other vascular regulators, such as von Willebrand factor and P-selectin (Fischer et al. 2011). RNase 1 could modulate the effects of RNA accumulation in the extracellular space secondary to tissue damage, malignancy, or death and thus prevent excess activation of macrophage activity, blood coagulation, and vascular permeabilization. Future studies of RNase 1 are likely to uncover not only new functions of the enzyme but also the biological roles of now unknown substrate RNAs.

Angiogenin

Angiogenin is named for its ability, which is unique among ptRNases, to stimulate blood vessel growth (Fett et al. 1985). This activity coincides with other unusual features. For example, angiogenin has catalytic activity against simple substrates that are 10^4 -fold lower than that of RNase 1 and other ptRNases (Shapiro et al. 1986; Leland et al. 2002). This deficiency is due, in part, to the occlusion of the enzymic active site by Gln117 (Acharya et al. 1994; Russo et al. 1994). Angiogenin has a well-known ability to cleave tRNAs (Saxena et al. 1992; Lyons et al. 2017).

Structural and signaling properties

Unlike RNase 1, angiogenin acts mainly within cells (Figure 5) (Sarangdhar and Allam 2021). Residues 60–68 compose a receptor-binding site that is necessary for cellular internalization (Hallahan et al. 1991; Raines et al. 1995). The circulating concentration of the enzyme (~ 400 ng/mL) is much higher than that required to stimulate its angiogenic activity (Bicknell and Vallee 1988), and this activity occurs in normal cells in a density-dependent manner (Hu et al. 2000). Several different proteins have been identified as receptors that mediate angiogenin activity, including syndecan-4 in astrocytes (Skorupa et al. 2012) and plexin B2 in multiple cell types (Yu et al. 2017). On the cell surface, angiogenin also binds to the EGFR and activates the ERK pathway (Liu et al. 2001; Wang et al. 2018b; Lee et al. 2019).

Angiogenin contains a nuclear localization signal (Arg31–Arg32–Arg33) (Moroianu and Riordan 1994), which drives the accumulation of the enzyme in the nucleolus and is required for its angiogenic activity (Xu et al. 2002). Normally, the nuclear localization of

angiogenin would be prevented by the association of the enzyme with cytosolic RI, to which angiogenin binds with femtomolar affinity (Lee et al. 1989). Angiogenin avoids association with RI by the disruption of favorable Coulombic interactions through phosphorylation, which is known to occur at Ser28, Ser37, and Ser87 (Figure 2(B)) and is mediated by PKC and CDK (Hoang and Raines 2017).

In the nucleus, angiogenin has been shown to cleave pRNA, which is normally associated with TIP5, a member of the NoRC chromatin remodeling complex. pRNA is responsible for the recruitment of TIP5 and NoRC to the rDNA promoter, which results in repression of rDNA transcription (Mayer et al. 2006, 2008). Cleavage of pRNA prevents its association with TIP5 and impairs recruitment of NoRC to the rDNA promoter, which results in derepression of rDNA and cell growth (Hoang and Raines 2017). This signaling pathway is unique among transcription factors, as no other proteins are known to reach the nucleus from the extracellular space and effect transcriptional change.

Angiogenin-mediated cell growth

In 1985, angiogenin was identified as a protein capable of stimulating blood vessel growth from human adenocarcinoma cells (Fett et al. 1985). Subsequently, angiogenin was shown to be secreted by multiple types of tumors, including those from prostate cancer (Yoshioka et al. 2006), oral squamous cell carcinoma (Kishimoto et al. 2012), and melanoma (Hartmann et al. 1999). Its production from cancer cells appears to be regulated by HIF-1 α (Kishimoto et al. 2012), suggesting a mechanism of action for tumor neovascularization in response to oxygen starvation. Angiogenin has also been studied as a biomarker in human colorectal cancer (Ramcharan et al. 2013), bladder cancer (Urquidi et al. 2012), and breast cancer (He et al. 2015), and its levels have been correlated with tumor aggressiveness. Consequently, angiogenin is a therapeutic target for the treatment of cancer. The knock-down of angiogenin in bladder cancer cells using siRNA did diminish tumor growth in a mouse xenograft model (Shu et al. 2015), and the neutralization of angiogenin with an antibody reduced the *in vitro* migration of triple-negative breast cancer cells (Dutta et al. 2014). An experimental small-molecule drug, 8-amino-5-(4'-hydroxybiphenyl-4ylazo)naphthalene-2-sulfonate, inhibits catalysis by angiogenin and deters the growth and vascularization of tumors in mouse xenograft models (Kao et al. 2002).

Angiogenin also acts in the placenta, endometrium, and ovarian follicle, tissues that normally undergo

extensive angiogenesis in adults (Reynolds et al. 2002). Angiogenin is present in ovarian follicular fluid. There, its production is stimulated by human chorionic gonadotropin—a hormone that promotes luteinization and angiogenesis during the formation of the corpus luteum (Koga et al. 2000). In studies of ovarian follicle transfer, angiogenin was identified to be a crucial factor in mediating the angiogenic and follicle-preserving effect of co-transplanted mesenchymal stem cells (Zhang et al. 2017), underscoring the importance of the ribonuclease for follicle survival and function. Angiogenin levels in the endometrium reflect the menstrual cycle, approximately doubling in the mid-to-late secretory phases relative to the proliferative phase (Koga et al. 2001). In pregnancy, angiogenin levels increase over time in the human placenta, reaching a maximum at term (Rajashekhar et al. 2002; Pavlov et al. 2003). In the placenta, angiogenin is found alongside markers of early vasculogenesis, such as VE-cadherin, CD34, and von Willebrand factor, and is present in developing fetal blood vessels (Pavlov et al. 2014).

Angiogenin can promote cell growth elsewhere than in the vascular endothelium. This versatility was observed first in the context of cancer; HeLa cells both secrete angiogenin and take it up, with angiogenin localizing to the nucleus and stimulating cell proliferation independent of cell density (Tsuji et al. 2005). Angiogenin has also demonstrated this activity in prostate cancer cells (Yoshioka et al. 2006). In addition, angiogenin appears to promote the growth of hepatocellular carcinoma cells in paracrine. These cells secrete angiogenin, which is taken up by tumor-associated hepatic stellate cells, spurring their activation and promoting the growth and metastasis of hepatocellular carcinoma cells (Han et al. 2014; Bárcena et al. 2015). Angiogenin is also expressed in the nervous system during embryonic development in mice and is localized to axonal growth cones, where it appears to promote axonal growth and neurite pathfinding (Subramanian and Feng 2007).

Angiogenin-mediated protection from cell stress

Loss-of-function mutations in the human *ANG* gene are associated with amyotrophic lateral sclerosis (ALS). In addition to its stimulation of neuronal growth, angiogenin has also been observed to have a protective effect on motoneurons in the context of ALS. Similar to the action of angiogenin in hepatocellular carcinoma, this activity is mediated in paracrine, by astrocyte uptake of motoneuron-secreted angiogenin (Skorupa et al. 2012). Angiogenin-stimulated astrocytes are then able to

protect motoneurons against excitotoxic stress through a mechanism that involves protein-level changes in astrocytes largely related to modulation of the extracellular matrix (Skorupa et al. 2013). This finding helps to explain many earlier studies that linked ALS to *ANG* mutations, many of which interfere with the catalytic activity of the enzyme (Greenway et al. 2006; Gellera et al. 2008). Nrf2 is a transcription factor that regulates the response of neurons and other cell types to oxidants and is likewise implicated in ALS. Angiogenin activates the Nrf2 pathway and thereby counteracts the deleterious consequences of reactive oxygen species. This link between *ANG* and Nrf2 provides a clear molecular basis for the neuroprotective activity of *ANG* and highlights the potential utility of angiogenin as a treatment for ALS (Hoang et al. 2019), though more data are necessary (Aluri et al. 2020).

A possible effector substrate for angiogenin in neurons is tRNA, which has been known to be an angiogenin substrate for many years (Saxena et al. 1992). This activity was first reported as cytotoxicity, as cleaved tRNAs arrest protein translation. Yet, it has been appreciated only recently that some, but not all (Su et al. 2019), tRNAs (which are tRNAs cleaved at the anticodon loop) are a product of catalysis by angiogenin that is induced by cellular stress (Yamasaki et al. 2009; Fu et al. 2009; Su et al. 2020). These tRNAs promote the formation of stress granules and inhibit protein synthesis, which is suggested to occur *via* displacement of the initiation factor eIF4G/A from mRNA (Ivanov et al. 2011). Nonetheless, tRNAs also exert a pro-survival effect in cells by binding to apoptotic protease-activating factor 1 (APAF1) in a manner that competitively blocks the binding of cytochrome c and the formation of the apoptosome (Saikia et al. 2014). SLFN2 binds to and protects tRNAs from oxidative stress-induced cleavage by the angiogenin, allowing activated T cells to maintain protein synthesis in the presence of reactive oxygen species that would otherwise inhibit translation (Yue et al. 2021).

Angiogenin has also been implicated to play roles in stem cell self-renewal. In hematopoietic stem/progenitor cells (HPSCs), angiogenin has been found to generate tRNAs and reduce protein synthesis, which is suggested to promote the stemness and quiescence of these cells while having a proliferative effect on myeloid progenitor cells (Goncalves et al. 2016). The mechanism by which angiogenin differentially regulates these two cell types is unknown.

Angiogenin has antimicrobial and anti-inflammatory activities. For example, angiogenin has been reported to be toxic to *Candida albicans*, *Streptococcus*




Figure 6. Phylogenetic tree of homologous ptRNases expressed in vertebrate species, with annotations highlighting the co-emergence of coagulation factors in given groups of species. Protein sequences of RNase 1 homologs from UniProtKB P07998 (human), P00683 (mouse), P00684 (rat), P61823 (cow), P30374 (chicken), P80287 (iguana), A0A151LY34 (alligator), P11916 (bullfrog), Q8UVX5_LITPI (Northern leopard frog), H9GD73_ANOCA (anole), A0A153RRZ8 (salmon), and A5HAK0 (zebrafish) were used to generate a phylogenetic tree based on protein sequence similarity with the program phylogeny.fr (Castresana 2000; Edgar 2004; Chevenet et al. 2006; Anisimova and Gascuel 2006; Guindon et al. 2010). The branch support value (red) is shown for each junction, and the number of substitutions per site is represented by line length. Line thickness at the termini of each leaf represents the number of ptRNase proteins reported to exist in each organism (Zhao et al. 1994; Irie et al. 1998; Beintema and Kleineidam 1998; Cho et al. 2005; Pizzo et al. 2006, 2008; Kazakou et al. 2008). Species without identified ptRNases are represented by dashed lines that are not to scale; these species are included to highlight the emergence of vertebrate coagulation factors. The emergence of angiogenins in fish, RNase 1-like proteins in amphibians, and RNA-sensitive coagulation factors (FXII, FXI, and prekallikrein [PK]) in amphibians and mammals are highlighted at the appropriate junctions (Doolittle and Surgenor 1962; Doolittle 2009).

pneumoniae, and *Mycobacterium tuberculosis* at micromolar concentrations (Hooper et al. 2003; Noschka et al. 2020), though its antimicrobial activity has been called into question (Avdeeva et al. 2006). Closely related proteins in the angiogenin subfamily in mice could have broader-spectrum antimicrobial activity (Hooper et al. 2003). Further, angiogenin is an acute-phase protein (Olson et al. 1998) that suppresses the effects of $\text{TNF}\alpha$ in fibroblasts, reducing levels of $\text{NF}\kappa\text{B}$, $\text{TNF}\alpha\text{R1}$, $\text{TNF}\alpha\text{R2}$, IL6, and IL8 and exerting a net anti-inflammatory effect (Lee et al. 2014; Park et al. 2020).

Emerging research on angiogenin suggests broader roles in cell growth and survival that extend beyond well-characterized roles in vascular growth. Future research on angiogenin might offer a better understanding of the mechanisms that determine whether angiogenin drives cellular proliferation or quiescence. Angiogenin is an attractive drug target for both antiangiogenic therapy in cancer (Kao et al. 2002) and

protection from cellular stress in neurodegeneration (Hoang et al. 2017), though more knowledge of the regulators of its activity could enable more selective targeting of the enzyme in specific biological niches.

Connections to vertebrate physiology

New roles identified for RNase 1 and angiogenin cluster broadly into the areas of regulating vascular homeostasis and cell growth/survival. Interestingly, some of these roles are tied to the innate physiology of vertebrates. ptRNase is exclusively present in vertebrates and is the only enzyme family limited to that subphylum (International Human Genome Sequencing Consortium 2001). The distribution of ptRNase subfamilies within vertebrates does, however, vary. Some vertebrate species, such as fish, express only angiogenin-like enzymes (Pizzo et al. 2006; Kazakou et al. 2008), and the diversification of the RNase 2 and 3 subfamilies occur only in

rodents (Cho et al. 2005). Some highlights of this evolutionary path are depicted in Figure 6.

Angiogenin could be the primordial ptRNase. This hypothesis is supported by the presence of enzymes in fish that are more similar to human angiogenin than to RNase 1 or other ptRNases (Kazakou et al. 2008). Additionally, angiogenin has three intramolecular disulfide bonds in contrast to the four in other ptRNases (Sorrentino 2010) (Figure 2(A,B)). That fourth disulfide bond is reduced more readily than the other three (Zhou and Strydom 1993), suggesting that it is less important to enzymic structure and function and was likely a later addition (Strydom 1998). Angiogenin is, then, likely to be nearly as old as vertebrates themselves (Figure 6), a reflection of its fundamental roles in cell growth and survival. The functions of angiogenin in the brain highlight this centrality, as the neural crest (which gives rise to protective glial cells), is not present in invertebrates (Green et al. 2015).

One of the other hallmarks of vertebrate physiology is the presence of a closed circulatory system with a continuous endothelial barrier (Muñoz-Chápuli et al. 2005), which requires a specialized blood clotting system (Doolittle and Surgenor 1962). In humans, the coagulation of blood plasma is achieved through a complex network of coagulation factor proteases, which are produced as zymogens and require activation from an upstream factor or series of factors. As a consequence of mechanical injury or inflammation, tissue factor (also known as Factor III) enters the bloodstream and forms a complex with the zymogen form of Factor VII, which potentiates its proteolytic activation. This TF-FVIIa complex acts as a “tenase”, performing proteolytic activation of FX to FXa. In parallel, intrinsic factor proteases, including FXII and prekallikrein, are activated in a protease-independent manner through contact with a variety of factors (such as proteins, glycans, or eRNA). FXIIa catalyzes the activation of FXI to FXIa, which in turn activates FIX to FIXa. Both FXIa and FIXa perpetuate further activation of FVII and themselves, and FIXa forms a tenase complex with Factor VIII and Factor V. Both cascades result in the generation of thrombin (i.e. Factor II), which catalyzes the subsequent cleavage and cross-linking of fibrinogen, ultimately yielding a stable fibrin clot (Smith et al. 2015).

Some vertebrates share the common thrombin-catalyzed coagulation pathway of humans but lack intrinsic factor proteases, such as FXII, FXI, and prekallikrein (Jiang and Doolittle 2003). Intrinsic factors emerged with the evolution of amphibians, with FXI appearing only in mammals (Doolittle 2009). Interestingly, the emergence of these RNA-sensitive coagulation factors

mirrors the presence of RNase 1. RNase 1 is more abundant in reptiles and birds than in fish that do not express these intrinsic coagulation factors, and much more highly expressed in mammals (Zendzian and Barnard 1967), suggesting that the evolution of RNA-responsive coagulation proteins and a cognate extracellular ribonuclease to regulate this activity were simultaneous.

Vertebrates also exhibit a much more specialized immune system than do invertebrates, with the emergence of major histocompatibility complex proteins, the T-cell receptor, and immunoglobulins. The rapid evolution of ptRNases has been used to suggest that these enzymes also contribute to the vertebrate-specific immune response (Beintema et al. 1988; Rosenberg et al. 1995; Rosenberg 2008; Goo and Cho 2013), as many family members (including angiogenin) are cytotoxic against a variety of microorganisms (*vide supra*). RNase 1 alone, however, is not cytotoxic (Eller and Raines 2020). Instead, RNase 1 modulates the activity of a broad array of cytokines and affects the interplay between innate and adaptive immunity *via* eRNA-mediated macrophage polarization, which influences T and B cell activity (Kleinert et al. 2016). The polarization of macrophages also appears to be a vertebrate-specific phenomenon, having been observed in fish but not other animals (Chettri et al. 2014). These multiple avenues implicate eRNA (and, by extension, RNase 1) as a regulator of the inflammation associated with cancer, autoimmune disease, and infectious disease.

Prospectus

Numerous new biological functions of pancreatic-type ribonucleases have been revealed in the past decade. Still, our appreciation of the functions of these enzymes in their endogenous environment has lagged. The effects of RNase 1 as an exogenous agent have been characterized in multiple models of cancer, vascular homeostasis, and injury. Angiogenin has been studied more thoroughly, but little information about the phenotype of constitutive knockout mice is available. Further study on the biological functions of these enzymes—RNase 1 outside of cells and angiogenin inside of cells—would advance our knowledge of the roles of the ptRNase superfamily and the functions of novel RNA populations and could guide the development of new therapeutic regimens.

Acknowledgments

We are grateful to C. S. Travis, E. C. Wralstad, and O. J. Molina for comments on the manuscript.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content of this paper.

Funding

Work in our laboratory on ribonucleases is supported by the NIH (grant R01 CA073808).

ORCID

Ronald T. Raines  <http://orcid.org/0000-0001-7164-1719>

References

- Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL. 1994. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. *Proc Natl Acad Sci USA*. 91(8):2915–2919.
- Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. 1985. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of *Schistosoma mansoni*. *Am J Trop Med Hyg*. 34(4):735–745.
- Altman S. 2011. Ribonuclease P. *Philos Trans R Soc Lond B Biol Sci*. 366(1580):2936–2941.
- Aluri KC, Salisbury JP, Prehn JHM, Agar JN. 2020. Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration. *Sci Rep*. 10(1):3715.
- Anfinsen CB. 1973. Principles that govern the folding of protein chains. *Science*. 181(4096):223–230.
- Anisimova M, Gascuel O. 2006. Approximate likelihood-ratio test for branches: a fast, accurate, and powerful alternative. *Syst Biol*. 55(4):539–552.
- Attery A, Batra JK. 2017. Mouse eosinophil associated ribonucleases: Mechanism of cytotoxic, antibacterial and antiparasitic activities. *Int J Biol Macromol*. 94(Pt A):445–450.
- Avdeeva SV, Chernukha MU, Shaginyan IA, Tarantul VZ, Naroditsky BS. 2006. Human angiogenin lacks specific antimicrobial activity. *Curr Microbiol*. 53(6):477–478.
- Bárcena C, Stefanovic M, Tutusaus A, Martinez-Nieto GA, Martinez L, García-Ruiz C, de Mingo A, Caballeria J, Fernandez-Checa JC, Mari M, et al. 2015. Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer. *Sci Rep*. 5:7916.
- Barlow GB, Whitear SH, Wilkinson AW. 1979. The excretion of alkaline ribonuclease by children undergoing surgery. *Br J Surg*. 66(6):412–414.
- Barnard EA. 1969. Biological function of pancreatic ribonuclease. *Nature*. 221(5178):340–344.
- Barrabés S, Pagès-Pons L, Radcliffe CM, Tabarés G, Fort E, Royle L, Harvey DJ, Moenner M, Dwek RA, Rudd PM, et al. 2007. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. *Glycobiology*. 17(4):388–400.
- Beintema JJ. 1986. Evolutionary role of posttranslational modifications of proteins, as illustrated by the glycosylation characteristics of the digestive enzyme pancreatic ribonuclease. *J Mol Evol*. 24(1–2):118–120.
- Beintema JJ, Kleinedam RG. 1998. The ribonuclease A superfamily: general discussion. *Cell Mol Life Sci*. 54(8):825–832.
- Beintema JJ, Schuller C, Irie M, Carsana A. 1988. Molecular evolution of the ribonuclease superfamily. *Prog Biophys Mol Biol*. 51(3):165–192.
- Benner SA. 1988. Extracellular ‘communicator RNA. *FEBS Lett*. 233:255–258.
- Benner SA, Allemann RK. 1989. The return of pancreatic ribonucleases. *Trends Biochem Sci*. 14(10):396–397.
- Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ. 2003. Dicer is essential for mouse development. *Nat Genet*. 35(3):215–217.
- Bicknell R, Vallee BL. 1988. Angiogenin activates endothelial cell phospholipase C. *Proc Natl Acad Sci USA*. 85(16):5961–5965.
- Blackburn P, Moore S. 1982. Pancreatic ribonuclease. *Enzymes*. 15:317–433.
- Boix E, Nogués MV. 2007. Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence. *Mol Biosyst*. 3(5):317–335.
- Cabrera-Fuentes HA, Niemann B, Grieshaber P, Wollbrueck M, Gehron J, Preissner KT, Boning A. 2015. RNase1 as a potential mediator of remote ischaemic preconditioning for cardioprotection. *Eur J Cardiothorac Surg*. 48(5):732–737.
- Cabrera-Fuentes HA, Ruiz-Meana M, Simsekylmaz S, Kostin S, Inserte J, Saffarzadeh M, Galuska SP, Vijayan V, Barba I, Barreto G, et al. 2014. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor- α in cardiac ischaemia/reperfusion injury. *Thromb Haemost*. 112(6):1110–1119.
- Cafaro V, De Lorenzo C, Piccoli R, Bracale A, Mastronicola MR, Di Donato A, D'Alessio G. 1995. The antitumor action of seminal ribonuclease and its quaternary conformations. *FEBS Lett*. 359(1):31–34.
- Castresana J. 2000. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. *Mol Biol Evol*. 17(4):540–552.
- Castro J, Ribó M, Benito A, Vilanova M. 2013. Mini-review: nucleus-targeted ribonucleases as antitumor drugs. *Curr Med Chem*. 20(10):1225–1231.
- Castro J, Ribó M, Vilanova M, Benito A. 2021. Strengths and challenges of secretory ribonucleases as antitumor agents. *Pharmaceutics*. 13(1):82.
- Chettri JK, Kuhn JA, Jaafar RM, Kania PW, Møller OS, Buchmann K. 2014. Epidermal response of rainbow trout to *Ichthyobodo necator*: Immunohistochemical and gene expression studies indicate a Th1-/Th2-like switch. *J Fish Dis*. 37(9):771–783.
- Chevenet F, Brun C, Banuls AL, Jacq B, Christen R. 2006. TreeDyn: towards dynamic graphics and annotations for analyses of trees. *BMC Bioinformatics*. 7:439.
- Cho S, Beintema JJ, Zhang J. 2005. The ribonuclease A superfamily of mammals and birds: Identifying new members and tracing evolutionary histories. *Genomics*. 85(2):208–220.

- Coombes E, Shakespeare P, Batstone G. 1977. Age and sex related reference values for serum ribonuclease. *Clin Chim Acta*. 79(1):271–275.
- Coombes EJ, Shakespeare PG, Batstone GF. 1978. Observations on serum and urine alkaline ribonuclease activity and urate after burn injury in man. *Clin Chim Acta*. 86(3):279–290.
- Cuchillo CM, Nogués MV, Raines RT. 2011. Bovine pancreatic ribonuclease: fifty years of the first enzymatic reaction mechanism. *Biochemistry*. 50(37):7835–7841.
- Cuchillo CM, Parés X, Guasch A, Barman T, Travers F, Nogués MV. 1993. The role of 2',3'-cyclic phosphodiesterases in the bovine pancreatic ribonuclease A catalysed cleavage of RNA: intermediates or products? *FEBS Lett*. 333(3): 207–210.
- D'Alessio G. 1993. New and cryptic biological messages from RNases. *Trends Cell Biol*. 3:106–109.
- D'Alessio G, Di Donato A, Parente A, Piccoli R. 1991. Seminal ribonuclease: a unique member of the ribonuclease superfamily. *Trends Biochem Sci*. 16(3):104–106.
- D'Alessio G, Riordan JF, editors. 1997. Ribonucleases: structures and functions. New York, NY: Academic Press.
- Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. 1988. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. *Cell Tissue Kinet*. 21(3): 169–182.
- Dickson KA, Haigis MC, Raines RT. 2005. Ribonuclease inhibitor: structure and function. *Prog Nucleic Acid Res Mol Biol*. 80:349–374.
- Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. 1998b. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. *Nucleic Acids Res*. 26(14):3358–3363.
- Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. 1998a. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. *J Infect Dis*. 177(6): 1458–1464.
- Doolittle RF. 2009. Step-by-step evolution of vertebrate blood coagulation. *Cold Spring Harb Symp Quant Biol*. 74: 35–40.
- Doolittle RF, Surgenor DM. 1962. Blood coagulation in fish. *Am J Physiol*. 203:964–970.
- Dostál J, Matoušek J. 1973. Isolation and some chemical properties of aspermatogenic substance from bull seminal vesicle fluid. *J Reprod Fertil*. 33(2):263–274.
- Dutta S, Bandyopadhyay C, Bottero V, Veetil MV, Wilson L, Pins MR, Johnson KE, Warshall C, Chandran B. 2014. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. *Mol Oncol*. 8(3): 483–507.
- Edgar RC. 2004. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res*. 32(5):1792–1797.
- Eller CH, Chao TY, Singarapu KK, Ouerfelli O, Yang G, Markley JL, Danishefsky SJ, Raines RT. 2015. Human cancer antigen Globo H is a cell-surface ligand for human Ribonuclease 1. *ACS Cent Sci*. 1(4):181–190.
- Eller CH, Lomax JE, Raines RT. 2014. Bovine brain ribonuclease is the functional homolog of human ribonuclease 1. *J Biol Chem*. 289(38):25996–26006.
- Eller CH, Raines RT. 2020. Antimicrobial synergy of a ribonuclease and a peptide secreted by human cells. *ACS Infect Dis*. 6(11):3083–3088.
- Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. 1985. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. *Biochemistry*. 24(20):5480–5486.
- Findlay D, Herries DG, Mathias AP, Rabin BR, Ross CA. 1961. The active site and mechanism of action of bovine pancreatic ribonuclease. *Nature*. 190:781–784.
- Fischer S, Gerriets T, Wessels C, Walberer M, Kostin S, Stolz E, Zheleva K, Hocke A, Hippenstiel S, Preissner KT. 2007. Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. *Blood*. 110(7): 2457–2465.
- Fischer S, Gesierich S, Griemert B, Schanzer A, Acker T, Augustin HG, Olsson AK, Preissner KT. 2013. Extracellular RNA liberates tumor necrosis factor- α to promote tumor cell trafficking and progression. *Cancer Res*. 73(16): 5080–5089.
- Fischer S, Grantzow T, Pagel JI, Tschernatsch M, Sperandio M, Preissner KT, Deindl E. 2012. Extracellular RNA promotes leukocyte recruitment in the vascular system by mobilising proinflammatory cytokines. *Thromb Haemost*. 108(4): 730–741.
- Fischer S, Nishio M, Dadkhahi S, Gansler J, Saffarzadeh M, Shibamiyama A, Kral N, Baal N, Koyama T, Deindl E, et al. 2011. Expression and localisation of vascular ribonucleases in endothelial cells. *Thromb Haemost*. 105(2):345–355.
- Fu H, Feng J, Liu Q, Sun F, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. 2009. Stress induces tRNA cleavage by angiogenin in mammalian cells. *FEBS Lett*. 583(2):437–442.
- Futami J, Tsushima Y, Murato Y, Tada H, Sasaki J, Seno M, Yamada H. 1997. Tissue-specific expression of pancreatic-type RNases and RNase inhibitor in humans. *DNA Cell Biol*. 16(4):413–419.
- Gajisiewicz JM, Smith SA, Morrissey JH. 2017. Polyphosphate and RNA differentially modulate the contact pathway of blood clotting. *J Biol Chem*. 292(5):1808–1814.
- Gansler J, Jaax M, Leiting S, Appel B, Greinacher A, Fischer S, Preissner KT. 2012. Structural requirements for the procoagulant activity of nucleic acids. *PLoS One*. 7(11): e50399.
- Garnett ER, Lomax JE, Mohammed BM, Gailani D, Sheehan JP, Raines RT. 2019. Phenotype of ribonuclease 1 deficiency in mice. *RNA*. 25(8):921–934.
- Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, Ratti A, Taroni F, Silani V. 2008. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. *Neurogenetics*. 9(1):33–40.
- Goncalves KA, Silberstein L, Li S, Severe N, Hu MG, Yang H, Scadden DT, Hu G-f. 2016. Angiogenin promotes hematopoietic regeneration by dichotomously regulating quiescence of stem and progenitor cells. *Cell*. 166(4):894–906.
- Goo SM, Cho S. 2013. The expansion and functional diversification of the mammalian ribonuclease A superfamily epitomizes the efficiency of multigene families at generating biological novelty. *Genome Biol Evol*. 5(11):2124–2140.
- Gotte G, Mahmoud Helmy A, Ercole C, Spadaccini R, Laurents DV, Donadelli M, Picone D. 2012. Double domain swapping in bovine seminal RNase: formation of distinct N-

- and C-swapped tetramers and multimers with increasing biological activities. *PLoS One*. 7(10):e46804.
- Green SA, Simoes-Costa M, Bronner ME. 2015. Evolution of vertebrates as viewed from the crest. *Nature*. 520(7548): 474–482.
- Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Patterson V, Swingle R, Kieran D, Prehn J, et al. 2006. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. *Nat Genet*. 38(4): 411–413.
- Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol*. 59(3):307–321.
- Hallahan TW, Shapiro R, Vallee BL. 1991. Dual site model for the organogenic activity of angiogenin. *Proc Natl Acad Sci USA*. 88(6):2222–2226.
- Han S, Han L, Yao Y, Sun H, Zan X, Liu Q. 2014. Activated hepatic stellate cells promote hepatocellular carcinoma cell migration and invasion via the activation of FAK-MMP9 signaling. *Oncol Rep*. 31(2):641–648.
- Harder J, Schroder JM. 2002. RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. *J Biol Chem*. 277(48):46779–46784.
- Hartmann A, Kunz M, Köstlin S, Gillitzer R, Toksoy A, Bröcker E-B, Klein CE. 1999. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. *Cancer Res*. 59(7):1578–1583.
- Hasselmann DO, Rappl G, Tilgen W, Reinhold U. 2001. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. *Clin Chem*. 47(8):1488–1489.
- He T, Qi F, Jia L, Wang S, Wang C, Song N, Fu Y, Li L, Luo Y. 2015. Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p. *Cancer Lett*. 368(1):115–125.
- Hirs C, Moore S, Stein WH. 1960. The sequence of the amino acid residues in performic acid-oxidized ribonuclease. *J Biol Chem*. 235:633–647.
- Hoang TT, Johnson DA, Raines RT, Johnson JA. 2019. Angiogenin activates the astrocytic Nrf2/antioxidant-response element pathway and thereby protects murine neurons from oxidative stress. *J Biol Chem*. 294(41): 15095–15103.
- Hoang TT, Raines RT. 2017. Molecular basis for the autonomous promotion of cell proliferation by angiogenin. *Nucleic Acids Res*. 45(2):818–831.
- Hoang TT, Smith TP, Raines RT. 2017. A boronic acid conjugate of angiogenin that shows ROS-responsive neuroprotective activity. *Angew Chem Int Ed Engl*. 56(10): 2619–2622.
- Hofsteenge J, Kieffer B, Matthies R, Hemmings BA, Stone SR. 1988. Amino acid sequence of the ribonuclease inhibitor from porcine liver reveals the presence of leucine-rich repeats. *Biochemistry*. 27(23):8537–8544.
- Hooper LV, Stappenbeck TS, Hong CV, Gordon JL. 2003. Angiogenins: a new class of microbicidal proteins involved in innate immunity. *Nat Immunol*. 4(3):269–273.
- Hu G-f, Xu C-j, Riordan JF. 2000. Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. *J Cell Biochem*. 76(3): 452–462.
- Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, et al. 2013. Characterization of human plasma-derived exosomal RNAs by deep sequencing. *BMC Genomics*. 14:319.
- Ilinskaya ON, Mahmud RS. 2014. Ribonucleases as antiviral agents. *Mol Biol*. 48(5):615–623.
- International Human Genome Sequencing Consortium. 2001. Initial sequencing and analysis of the human genome. *Nature*. 409:860–921.
- Irie M, Nitta K, Nonaka T. 1998. Biochemistry of frog ribonucleases. *Cell Mol Life Sci*. 54(8):775–784.
- Isaacs P. 1981. Non-specificity of elevated serum ribonuclease as a pancreatic tumour marker. *Digestion*. 22(2):101–107.
- Ivanov P, Emara MM, Villen J, Gygi SP, Anderson P. 2011. Angiogenin-induced tRNA fragments inhibit translation initiation. *Mol Cell*. 43(4):613–623.
- Jiang Y, Doolittle RF. 2003. The evolution of vertebrate blood coagulation as viewed from a comparison of puffer fish and sea squirt genomes. *Proc Natl Acad Sci USA*. 100(13): 7527–7532.
- Johnson RJ, McCoy JG, Bingman CA, Phillips GN, Jr., Raines RT. 2007. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. *J Mol Biol*. 368(2):434–449.
- Jones W. 1920. The action of boiled pancreas extract on yeast nucleic acid. *J Am Physiol*. 52(1):203–207.
- Kamm RC, Smith AG. 1972. Nucleic acid concentrations in normal human plasma. *Clin Chem*. 18(6):519–522.
- Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, et al. 2007. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. *Proc Natl Acad Sci USA*. 104(15):6388–6393.
- Kao RYT, Jenkins JL, Olson KA, Key ME, Fett JW, Shapiro R. 2002. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. *Proc Natl Acad Sci USA*. 99(15):10066–10071.
- Kartha G, Bello J, Harker D. 1967. Tertiary structure of ribonuclease. *Nature*. 213(5079):862–865.
- Kazakou K, Holloway DE, Prior SH, Subramanian V, Acharya KR. 2008. Ribonuclease A homologues of the zebrafish: polymorphism, crystal structures of two representatives and their evolutionary implications. *J Mol Biol*. 380(1): 206–222.
- Kilgore HR, Latham AP, Ressler VT, Zhang B, Raines RT. 2020. Structure and dynamics of N-glycosylated human ribonuclease 1. *Biochemistry*. 59(34):3148–3156.
- Kim J-S, Souček J, Matoušek J, Raines RT. 1995a. Structural basis for the biological activities of bovine seminal ribonuclease. *J Biol Chem*. 270(18):10525–10530.
- Kim J-S, Souček J, Matoušek J, Raines RT. 1995b. Mechanism of ribonuclease cytotoxicity. *J Biol Chem*. 270(52): 31097–31102.
- Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Okui T, Hu GF, Sasaki A. 2012. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer. *Oral Oncol*. 48(11):1120–1127.
- Kleinert E, Langenmayer MC, Reichart B, Kindermann J, Griemert B, Blutke A, Troidl K, Mayr T, Grantzow T, Noyan F, et al. 2016. Ribonuclease (RNase) prolongs survival of grafts in experimental heart transplantation. *J Am Heart Assoc*. 5:e003429.

- Klink TA, Woycechowsky KJ, Taylor KM, Raines RT. 2000. Contribution of disulfide bonds to the conformational stability and catalytic activity of ribonuclease A. *Eur J Biochem.* 267(2):566–572.
- Kobe B, Deisenhofer J. 1993. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. *Nature.* 366(6457):751–756.
- Koga K, Osuga Y, Tsutsumi O, Momoeda M, Suenaga A, Kugu K, Fujiwara T, Takai Y, Yano T, Taketani Y. 2000. Evidence for the presence of angiogenin in human follicular fluid and the up-regulation of its production by human chorionic gonadotropin and hypoxia. *J Clin Endocrinol Metab.* 85(9):3352–3355.
- Koga K, Osuga Y, Tsutsumi O, Yano T, Yoshino O, Takai Y, Matsumi H, Hiroi H, Kugu K, Momoeda M, et al. 2001. Demonstration of angiogenin in human endometrium and its enhanced expression in endometrial tissues in the secretory phase and the decidua. *J Clin Endocrinol Metab.* 86(11):5609–5614.
- Krutsikh A, Poliandri A, Cabrera-Sharp V, Dacheux JL, Poutanen M, Huhtaniemi I. 2012. Epididymal protein RNase10 is required for post-testicular sperm maturation and male fertility. *. 26(10):4198–4209.*
- Kutas V, Bertök L, Szabó L. 1969. Effect of endotoxin on the serum ribonuclease activity in rats. *J Bacteriol.* 100(1): 550–551.
- Landre JB, Hewett PW, Olivot JM, Friedl P, Ko Y, Sachinidis A, Moenner M. 2002. Human endothelial cells selectively express large amounts of pancreatic-type ribonuclease (RNase 1). *J Cell Biochem.* 86(3):540–552.
- Lee FS, Shapiro R, Vallee BL. 1989. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. *Biochemistry.* 28(1):225–230.
- Lee FS, Vallee BL. 1993. Structure and action of mammalian ribonuclease (angiogenin) inhibitor. *Prog Nucleic Acid Res Mol Biol.* 44:1–30.
- Lee H-H, Wang Y-N, Hung M-C. 2019. Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. *Mol Aspects Med.* 70: 106–116.
- Lee H-H, Wang Y-N, Yang W-H, Xia W, Wei Y, Chan L-C, Wang Y-H, Jiang Z, Xu S, Yao J, et al. 2021. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. *Nat Commun.* 12(1):2788.
- Lee JE, Raines RT. 2005. Cytotoxicity of bovine seminal ribonuclease: monomer versus dimer. *Biochemistry.* 44(48): 15760–15767.
- Lee JE, Raines RT. 2008. Ribonucleases as novel chemotherapeutics: the ranpirnase example. *BioDrugs.* 22(1):53–58.
- Lee SH, Kim KW, Min K-M, Kim K-W, Chang S-I, Kim JC. 2014. Angiogenin reduces immune inflammation via inhibition of TANK-binding kinase 1 expression in human corneal fibroblast cells. *Mediators Inflamm.* 2014:861435.
- Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ. 1989. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. *J Immunol.* 142(12):4428–4434.
- Leland PA, Staniszewski KE, Park C, Kelemen BR, Raines RT. 2002. The ribonucleolytic activity of angiogenin. *Biochemistry.* 41(4):1343–1350.
- Li J, Boix E. 2021. Host defence RNases as antiviral agents against enveloped single stranded RNA viruses. *Virulence.* 12(1):444–469.
- Liu S, Yu D, Xu Z, Riordan JF, Hu G. 2001. Angiogenin activates Erk1/2 in human umbilical vein endothelial cells. *Biochem Biophys Res Commun.* 287(1):305–310.
- Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM, Lee JC, Huang DP. 1999. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. *Clin Chem.* 45(8 Pt 1):1292–1294.
- Lomax JE, Bianchetti CM, Chang A, Phillips GN Jr., Fox BG, Raines RT. 2014. Functional evolution of ribonuclease inhibitor: Insights from birds and reptiles. *J Mol Biol.* 426(17):3041–3056.
- Lomax JE, Eller CH, Raines RT. 2012. Rational design and evaluation of mammalian ribonuclease cytotoxins. *Methods Enzymol.* 502:273–290.
- Lomax JE, Eller CH, Raines RT. 2017. Comparative functional analysis of ribonuclease 1 homologs: molecular insights into evolving vertebrate physiology. *Biochem J.* 474(13): 2219–2233.
- Lu L, Li J, Moussaoui M, Boix E. 2018. Immune modulation by human secreted RNases at the extracellular space. *Front Immunol.* 9:1012.
- Lyons SM, Fay MM, Akiyama Y, Anderson PJ, Ivanov P. 2017. RNA biology of angiogenin: Current state and perspectives. *RNA Biol.* 14(2):171–178.
- Maor D, Klein ME, Kenady DE, Chretien PB, Mardiney MR. 1978. Carcinoma of the lung and cigarette smoking. Effect on serum ribonuclease activity. *JAMA.* 239(26):2766–2768.
- Maor D, Mardiney MR Jr. 1978. Alteration of human serum ribonuclease activity in malignancy. *Crit Rev Clin Lab Sci.* 10(1):89–111.
- Marshall GR, Feng JA, Kuster DJ. 2008. Back to the future: ribonuclease A. *Biopolymers.* 90(3):259–277.
- Matoušek J. 1973. The effect of bovine seminal ribonuclease (AS RNase) on cells of Crocker tumour in mice. *Experientia.* 29(7):858–859.
- Mayer C, Neubert M, Grummt I. 2008. The structure of NoRC-associated RNA is crucial for targeting the chromatin remodelling complex NoRC to the nucleolus. *EMBO Rep.* 9(8):774–780.
- Mayer C, Schmitz KM, Li J, Grummt I, Santoro R. 2006. Intergenic transcripts regulate the epigenetic state of rRNA genes. *Mol Cell.* 22(3):351–361.
- Merlino A, Ercole C, Picone D, Pizzo E, Mazzarella L, Sica F. 2008. The buried diversity of bovine seminal ribonuclease: shape and cytotoxicity of the swapped non-covalent form of the enzyme. *J Mol Biol.* 376(2):427–437.
- Merrifield RB. 1986. Solid phase synthesis. *Science.* 232(4748): 341–348.
- Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MÁ, Bernad A, Sánchez-Madrid F. 2011. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat Commun.* 2:282.
- Mizuta K, Awazu S, Yasuda T, Kishi K. 1990. Purification and characterization of three ribonucleases from human kidney: comparison with urine ribonucleases. *Arch Biochem Biophys.* 281(1):144–151.

- Molina HA, Kierszenbaum F, Hamann KJ, Gleich GJ. 1988. Toxic effects produced or mediated by human eosinophil granule components on *Trypanosoma cruzi*. *Am J Trop Med Hyg.* 38(2):327–334.
- Moore S, Stein WH. 1973. Chemical structures of pancreatic ribonuclease and deoxyribonuclease. *Science.* 180(4085): 458–464.
- Moroianu J, Riordan JF. 1994. Identification of the nucleolar targeting signal of human angiogenin. *Biochem Biophys Res Commun.* 203(3):1765–1772.
- Muñoz-Chápuli R, Carmona R, Guadix JA, Macías D, Pérez-Pomares JM. 2005. The origin of the endothelial cells: an evo-devo approach for the invertebrate/vertebrate transition of the circulatory system. *Evol Dev.* 7(4):351–358.
- Murthy BS, Sirdeshmukh R. 1992. Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor. *Biochem J.* 281(2): 343–348.
- Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U, Koyama T, Niepmann M, Trusheim H, Engelmann B, et al. 2005. Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). *Biochem J.* 385(Pt 3):831–838.
- Nicholson AW, editor. 2011. Ribonucleases. Berlin: Springer.
- Noschka R, Gerbl F, Löffler F, Kubis J, Rodríguez AA, Mayer D, Grieshaber M, Holch A, Raasholm M, Forssmann W-G, et al. 2020. Unbiased identification of angiogenin as an endogenous antimicrobial protein with activity against virulent *Mycobacterium tuberculosis*. *Front Microbiol.* 11: 618278.
- Olson KA, Verselis SJ, Fett JW. 1998. Angiogenin is regulated *in vivo* as an acute phase protein. *Biochem Biophys Res Commun.* 242(3):480–483.
- Oribe M. 1984. [Serum ribonuclease in rheumatic disease. I. Serum alkaline ribonuclease activities in rheumatic diseases, especially in malignant rheumatoid arthritis]. *Fukuoka Igaku Zasshi.* 75(9):524–533.
- Park C, Raines RT. 2001. Quantitative analysis of the effect of salt concentration on enzymatic catalysis. *J Am Chem Soc.* 123(46):11472–11479.
- Park J, Kim JT, Lee SJ, Kim JC. 2020. The anti-inflammatory effects of angiogenin in an endotoxin induced uveitis in rats. *IJMS.* 21(2):413.
- Pavlov N, Frendo JL, Guibourdenche J, Degrelle SA, Evain-Brion D, Badet J. 2014. Angiogenin expression during early human placental development; association with blood vessel formation. *Biomed Res Int.* 2014:781632.
- Pavlov N, Hatzi E, Bassaglia Y, Frendo JL, Evain Brion D, Badet J. 2003. Angiogenin distribution in human term placenta, and expression by cultured trophoblastic cells. *Angiogenesis.* 6(4):317–330.
- Pizzo E, Buonanno P, Di Maro A, Ponticelli S, De Falco S, Quarto N, Cubellis MV, D'Alessio G. 2006. Ribonucleases and angiogenins from fish. *J Biol Chem.* 281(37): 27454–27460.
- Pizzo E, Varcamonti M, Di Maro A, D Maro A, Zanfardino A, Giancola C, D'Alessio G. 2008. Ribonucleases with angiogenic and bactericidal activities from the Atlantic salmon. *FEBS J.* 275(6):1283–1295.
- Raines RT. 1998. Ribonuclease A. *Chem Rev.* 98(3):1045–1065.
- Raines RT, Toscano MP, Nierengarten DM, Ha JH, Auerbach R. 1995. Replacing a surface loop endows ribonuclease A with angiogenic activity. *J Biol Chem.* 270(29): 17180–17184.
- Rajashekhar G, Loganath A, Roy AC, Wong YC. 2002. Expression and localization of angiogenin in placenta: enhanced levels at term over first trimester villi. *Mol Reprod Dev.* 62(2):159–166.
- Ramcharan SK, Lip GY, Stonelake PS, Blann AD. 2013. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer. *Eur J Clin Invest.* 43(8):801–808.
- Reddi KK, Holland JF. 1976. Elevated serum ribonuclease in patients with pancreatic cancer. *Proc Natl Acad Sci USA.* 73(7):2308–2310.
- Reijns MA, Rabe B, Rigby RE, Mill P, Astell KR, Lettice LA, Boyle S, Leitch A, Keighren M, Kilanowski F, et al. 2012. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. *Cell.* 149(5):1008–1022.
- Ressler VT, Raines RT. 2019. Consequences of the endogenous N-glycosylation of human ribonuclease 1. *Biochemistry.* 58(7):987–996.
- Reynolds LP, Grazul-Bilska AT, Redmer DA. 2002. Angiogenesis in the female reproductive organs: pathological implications. *Int J Exp Pathol.* 83(4):151–163.
- Ribó M, Beintema JJ, Osset M, Fernández E, Bravo J, de Llorens R, Cuchillo CM. 1994. Heterogeneity in the glycosylation pattern of human pancreatic ribonuclease. *Biol Chem Hoppe Seyler.* 375(5):357–363.
- Richards FM, Vithayathil PJ. 1959. The preparation of subtilisin-modified ribonuclease and the separation of the peptide and protein components. *J Biol Chem.* 234(6): 1459–1465.
- Richards FM, Wyckoff HW. 1971. Bovine pancreatic ribonuclease. *Enzymes.* 4:647–806.
- Rosenberg HF. 2008. RNase A ribonucleases and host defense: an evolving story. *J Leukoc Biol.* 83(5):1079–1087.
- Rosenberg HF, Dyer KD, Tiffany HL, Gonzalez M. 1995. Rapid evolution of a unique family of primate ribonuclease genes. *Nat Genet.* 10(2):219–223.
- Ruoppolo M, Vinci F, Klink TA, Raines RT, Marino G. 2000. Contribution of individual disulfide bonds to the oxidative folding of ribonuclease A. *Biochemistry.* 39(39): 12033–12042.
- Russo N, Shapiro R, Acharya KR, Riordan JF, Vallee BL. 1994. Role of glutamine-117 in the ribonucleolytic activity of human angiogenin. *Proc Natl Acad Sci USA.* 91(8): 2920–2924.
- Rutkoski TJ, Raines RT. 2008. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. *Curr Pharm Biotechnol.* 9(3):185–189.
- Saikia M, Jobava R, Parisien M, Putnam A, Krokowski D, Gao X-H, Guan B-J, Yuan Y, Jankowsky E, Feng Z, et al. 2014. Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. *Mol Cell Biol.* 34(13):2450–2463.
- Sajdel-Sulkowska EM, Marotta CA. 1984. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. *Science.* 225(4665):947–949.
- Sarangdhar MA, Allam R. 2021. Angiogenin (ANG)—ribonuclease inhibitor (RNH1) system in protein synthesis and disease. *IJMS.* 22(3):1287.

- Savelyeva AV, Kuligina EV, Bariakin DN, Kozlov VV, Ryabchikova EI, Richter VA, Semenov DV. 2017. Variety of RNAs in peripheral blood cells, plasma, and plasma fractions. *Biomed Res Int*. 2017:7404912.
- Saxena SK, Rybak SM, Davey RT Jr., Youle RJ, Ackerman EJ. 1992. Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. *J Biol Chem*. 267(30):21982–21986.
- Schulenburg C, Weininger U, Neumann P, Meiselbach H, Stubbs MT, Sticht H, Balbach J, Ulbrich-Hofmann R, Arnold U. 2010. Impact of the C-terminal disulfide bond on the folding and stability of onconase. *ChemBioChem*. 11(7):978–986.
- Shapiro R, Riordan JF, Vallee BL. 1986. Characteristic ribonucleolytic activity of human angiogenin. *Biochemistry*. 25(12):3527–3532.
- Shu J, Huang M, Tian Q, Shui Q, Zhou Y, Chen J. 2015. Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway. *J Mol Histol*. 46(2):157–171.
- Sigulem DM, Brasel JA, Velasco EG, Rosso P, Winick M. 1973. Plasma and urine ribonuclease as a measure of nutritional status in children. *Am J Clin Nutr*. 26(8):793–797.
- Simsekylmaz S, Cabrera-Fuentes HA, Meiler S, Kostin S, Baumer Y, Liehn EA, Weber C, Boisvert WA, Preissner KT, Zerneck A. 2014. Role of extracellular RNA in atherosclerotic plaque formation in mice. *Circulation*. 129(5):598–606.
- Skorupa A, King MA, Aparicio IM, Dussmann H, Coughlan K, Breen B, Kieran D, Concannon CG, Marin P, Prehn JHM. 2012. Motoneurons secrete angiogenin to induce RNA cleavage in astroglia. *J Neurosci*. 32(15):5024–5038.
- Skorupa A, Urbach S, Vigy O, King MA, Chaumont-Dubel S, Prehn JH, Marin P. 2013. Angiogenin induces modifications in the astrocyte secretome: relevance to amyotrophic lateral sclerosis. *J Proteomics*. 91:274–285.
- Smith SA, Travers RJ, Morrissey JH. 2015. How it all starts: initiation of the clotting cascade. *Crit Rev Biochem Mol Biol*. 50(4):326–336.
- Sorrentino S. 2010. The eight human “canonical” ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. *FEBS Lett*. 584(11):2194–2200.
- Sorrentino S, Libonati M. 1994. Human pancreatic-type and nonpancreatic-type ribonucleases: a direct side-by-side comparison of their catalytic properties. *Arch Biochem Biophys*. 312(2):340–348.
- Spencer JD, Schwaderer AL, Eichler T, Wang H, Kline J, Justice SS, Cohen DM, Hains DS. 2014. An endogenous ribonuclease inhibitor regulates the antimicrobial activity of ribonuclease 7 in the human urinary tract. *Kidney Int*. 85(5):1179–1191.
- Stieger P, Daniel JM, Tholen C, Dutzmann J, Knopp K, Gunduz D, Aslam M, Kampschulte M, Langheinrich A, Fischer S, et al. 2017. Targeting of extracellular RNA reduces edema formation and infarct size and improves survival after myocardial infarction in mice. *J Am Heart Assoc*. 6:e004541.
- Strong LE, Kink JA, Pensinger D, Mei B, Shahan M, Raines RT. 2012a. Efficacy of ribonuclease QBI-139 in combination with standard of care therapies. *Cancer Res*. 72(Suppl 1):1838.
- Strong LE, Kink JA, Mei B, Shahan MN, Raines RT. 2012b. First in human phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors. *J Clin Oncol*. 30(Suppl):TPS3113.
- Stroun M, Anker P, Beljanski M, Henri J, Lederrey C, Ojha M, Maurice PA. 1978. Presence of RNA in the nucleoprotein complex spontaneously released by human lymphocytes and frog auricles in culture. *Cancer Res*. 38(10):3546–3554.
- Strydom DJ. 1998. The angiogenins. *Cell Mol Life Sci*. 54(8):811–824.
- Su Z, Kescu C, Malik A, Shibata E, Dutta A. 2019. Angiogenin generates specific stress-induced tRNA halves and is not involved in tRF-3-mediated gene silencing. *J Biol Chem*. 294(45):16930–16941.
- Su Z, Wilson B, Kumar P, Dutta A. 2020. Noncanonical roles of tRNAs: tRNA fragments and beyond. *Annu Rev Genet*. 54:47–69.
- Subramanian V, Feng Y. 2007. A new role for angiogenin in neurite growth and pathfinding: Implications for amyotrophic lateral sclerosis. *Hum Mol Genet*. 16(12):1445–1453.
- Sun X, Wiedeman A, Agrawal N, Teal TH, Tanaka L, Hudkins KL, Alpers CE, Bolland S, Buechler MB, Hamerman JA, et al. 2013. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. *J Immunol*. 190(6):2536–2543.
- Sznajd J, Magdoń M, Naskalski J, Uracz R, Wojcikiewicz O. 1981. Serum ribonuclease activity in acute myocardial infarction. *Cor Vasa*. 23(4):241–247.
- Thomas SP, Hoang TT, Ressler VT, Raines RT. 2018. Human angiogenin is a potent cytotoxin in the absence of ribonuclease inhibitor. *RNA*. 24(8):1018–1027.
- Thomas SP, Kim E, Kim J-S, Raines RT. 2016. Knockout of the ribonuclease inhibitor gene leaves human cells vulnerable to secretory ribonucleases. *Biochemistry*. 55(46):6359–6362.
- Thompson JE, Venegas FD, Raines RT. 1994. Energetics of catalysis by ribonucleases: fate of the 2',3'-cyclic phosphodiester intermediate. *Biochemistry*. 33(23):7408–7414.
- Tsuji T, Sun Y, Kishimoto K, Olson KA, Liu S, Hirukawa S, Hu G-f. 2005. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. *Cancer Res*. 65(4):1352–1360.
- Turchinovich A, Weiz L, Langheinrich A, Burwinkel B. 2011. Characterization of extracellular circulating microRNA. *Nucleic Acids Res*. 39(16):7223–7233.
- Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. 2012. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. *Urology*. 79(5):1185.e1–6.
- Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 9(6):654–659.
- Venge P, Byström J, Carlson M, Håkansson L, Karawaczyk M, Peterson C, Sevéus L, Trulsson A. 1999. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. *Clin Exp Allergy*. 29(9):1172–1186.
- Vicentini AM, Kieffer B, Matthies R, Meyhack B, Hemmings BA, Stone SR, Hofsteenge J. 1990. Protein chemical and kinetic characterization of recombinant porcine

- ribonuclease inhibitor expressed in *Saccharomyces cerevisiae*. *Biochemistry*. 29(37):8827–8834.
- Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. 2011. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol*. 13(4):423–433.
- Walberer M, Tschernatsch M, Fischer S, Ritschel N, Volk K, Friedrich C, Bachmann G, Mueller C, Kaps M, Nedelmann M, et al. 2009. RNase therapy assessed by magnetic resonance imaging reduces cerebral edema and infarction size in acute stroke. *CNR*. 6(1):12–19.
- Wang Y, Medvid R, Melton C, Jaenisch R, Billeloch R. 2007. DGC8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. *Nat Genet*. 39(3):380–385.
- Wang Y-N, Lee H-H, Chou C-K, Yang W-H, Wei Y, Chen C-T, Yao J, Hsu JL, Zhu C, Ying H, et al. 2018b. Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer. *Cancer Cell*. 33(4):752–769.
- Wang Y-N, Lee H-H, Hung M-C. 2018a. A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. *J Biomed Sci*. 25(1):83.
- Weickmann JL, Olson EM, Glitz DG. 1984. Immunological assay of pancreatic ribonuclease in serum as an indicator of pancreatic cancer. *Cancer Res*. 44(4):1682–1687.
- Westmuckett AD, Nguyen EB, Herlea-Pana OM, Alvau A, Salicioni AM, Moore KL. 2014. Impaired sperm maturation in RNASE9 knockout mice. *Biol Reprod*. 90(6):120.
- Wieczorek AJ, Rhyner C, Block LH. 1985. Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. *Proc Natl Acad Sci USA*. 82(10):3455–3459.
- Windsor IW, Dudley DM, O'Connor DH, Raines RT. 2021. Ribonuclease zymogen induces cytotoxicity upon HIV-1 infection. *AIDS Res Ther*. 18(1):77.
- Windsor IW, Graff CJ, Raines RT. 2019. Circular zymogens of human ribonuclease 1. *Protein Sci*. 28(9):1713–1719.
- Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. 1993. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. *J Biol Chem*. 268(14):10686–10693.
- Xu Z-p, Tsuji T, Riordan JF, Hu G-f. 2002. The nuclear function of angiogenin in endothelial cells is related to rRNA production. *Biochem Biophys Res Commun*. 294(2):287–292.
- Yamasaki S, Ivanov P, Hu GF, Anderson P. 2009. Angiogenin cleaves tRNA and promotes stress-induced translational repression. *J Cell Biol*. 185(1):35–42.
- Yáñez-Mó M, Siljander PR-M, Andreu Z, Bedina Zavec A, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, et al. 2015. Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles*. 4:27066.
- Yasuda T, Nadano D, Takeshita H, Kishi K. 1993. Two distinct secretory ribonucleases from human cerebrum: purification, characterization and relationships to other ribonucleases. *Biochem J*. 296(3):617–625.
- Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu G-f. 2006. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. *Proc Natl Acad Sci USA*. 103(39):14519–14524.
- Yu W, Goncalves KA, Li S, Kishikawa H, Sun G, Yang H, Vanli N, Wu Y, Jiang Y, Hu MG, et al. 2017. Plexin-B2 mediates physiologic and pathologic functions of angiogenin. *Cell*. 171(4):849–864.
- Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, et al. 2016. Plasma extracellular RNA profiles in healthy and cancer patients. *Sci Rep*. 6(1):19413.
- Yue T, Zhan X, Zhang D, Jain R, Wang K-W, Choi JH, Misawa T, Su L, Quan J, Hildebrand S, Xu D, et al. 2021. SLFN2 protection of tRNAs from stress-induced cleavage is essential for T cell-mediated immunity. *Science*. 372(6543):eaba4220.
- Zendzian EN, Barnard EA. 1967. Distributions of pancreatic ribonuclease, chymotrypsin, and trypsin in vertebrates. *Arch Biochem Biophys*. 122(3):699–713.
- Zhang J, Dyer KD, Rosenberg HF. 2002. RNase 8, a novel RNase A superfamily ribonuclease expressed uniquely in placenta. *Nucleic Acids Res*. 30(5):1169–1175.
- Zhang Y, Xia X, Yan J, Yan L, Lu C, Zhu X, Wang T, Yin T, Li R, Chang HM, et al. 2017. Mesenchymal stem cell-derived angiogenin promotes primordial follicle survival and angiogenesis in transplanted human ovarian tissue. *Reprod Biol Endocrinol*. 15(1):18.
- Zhao W, Beintema JJ, Hofsteenge J. 1994. The amino acid sequence of iguana (*Iguana iguana*) pancreatic ribonuclease. *Eur J Biochem*. 219(1–2):641–646.
- Zhou H-M, Strydom DJ. 1993. The amino acid sequence of human ribonuclease 4, a highly conserved ribonuclease that cleaves specifically on the 3' side of uridine. *Eur J Biochem*. 217(1):401–410.